Patent ID: 11925673
Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method for the treatment of age-related macular degeneration in a subject, the method comprising the step of increasing or decreasing in the subject the amount of an inner-blood-retinal-barrier (iBRB) protein selected from claudin-1, claudin-3, claudin-12, occludin, tricellulin, Lipolysis-stimulated lipoprotein receptor (LSR), zonula occluden-1 (ZO-1), junctional adhesion molecule (JAM), and combinations each thereof; and a circadian clock protein_selected from period-1 (Per-1), period-2 (Per-2), period-3 (Per-3), cryptochrome-1 (Cry-1), cryptochrome-2 (Cry-2), Clock, brain and muscle aryl hydrocarbon receptor nuclear translocator like-1 (BMAL-1), brain and muscle aryl hydrocarbon receptor nuclear translocator like-2 (BMAL-2), Rev-ErbA alpha (NR1 D1), and combinations each thereof.